Vir, prostate cancer

Vir Biotechnology: A Rocket Off Phase 1 Data... What Could Go Wrong?
Vir Biotechnology's recent share price rally is driven by their promising cancer program. Having shot to over a $1.5B market cap, see if VIR stock is a Buy now.
Vir Biotechnology Catapults 58% On Promising Results In Cancer Treatment
Vir Biotechnology announced promising results Wednesday for a pair of cancer treatments, and Vir stock catapulted by double digits.
Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why
Vir Biotechnology's Phase 1 trials reveal promising safety and efficacy for dual-masked T-cell engagers targeting HER2 and PSMA in cancer therapies.
Vir Biotech upgraded at Morgan Stanley on cancer drug data
Vir Biotechnology (VIR) stock was upgraded by Morgan Stanley after the company posted trial data for two antitumor agents developed with Sanofi (SNY). Read more here.
Vir Biotechnology Reports Positive Phase 2 Results, Shares Surge by 58%
Following the publication of encouraging results from Phase 2 studies for two investigational cancer treatments, Vir Biotechnology ( VIR, Financials) saw a notable 58% increase in its stock price, thereby emphasizing developments in its oncology pipeline.
Vir Biotech Shares Rise on Positive Data for Cancer Treatments
Vir Biotechnology shares were up 67% to $13.15 after the company reported encouraging initial Phase 1 data for its dual-masked T-cell engagers, VIR-5818 and VIR-5500. The clinical-stage biopharmaceutical company said VIR-5818 targets HER2-expressing solid tumors,
Vir Biotechnology presents safety, efficacy data in VIR-5818 and VIR-5500 trials
Vir Biotechnology (VIR) is presenting initial Phase 1 data from two of its dual-masked T-cell engagers: VIR-5818, targeting a variety of
Vir Biotechnology Reports Promising Trial Results for Cancer Therapies
Vir Biotechnology ( (VIR) ) has issued an update. Vir Biotechnology announced promising Phase 1 trial results for its dual-masked T-cell engagers, VIR-5818 and VIR-5500, targeting HER2-expressing solid tumors and PSMA in metastatic castration-resistant prostate cancer respectively.
Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why
Vir Biotechnology's Phase 1 data highlights early promise for T-cell engagers targeting HER2-positive tumors and prostate ...
Vir Biotechnology: Buy Rating Supported by Promising TCE Programs and Strategic Partnerships
H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Vir Biotechnology (VIR – Research Report) today and set a price target of ...
Hosted on MSN1d
Morgan Stanley Upgrades Vir Biotechnology (VIR)
Fintel reports that on January 9, 2025, Morgan Stanley upgraded their outlook for Vir Biotechnology (NasdaqGS:VIR) from Equal ...
Vir Biotechnology, Once a Hot Covid Stock, Finds New Path Forward in Cancer
Shares of the battered biotech Vir Biotechnology were up more than 70% on Wednesday, as the company reported its first positive data since it executed a major pivot last summer. A hot stock during the ...
Vir Biotechnology’s Promising TCE Oncology Assets Earn Buy Rating from Joseph Stringer
Vir Biotechnology (VIR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Stringer ...
bovnews2d
Vir Biotechnology (VIR) Makes Big Waves: Why Today’s Stock Surge Matters
Vir Biotechnology, Inc. (Nasdaq: VIR) is experiencing a massive surge in the stock market, climbing an impressive +74.08% or $5.85 to $13.74 in Wednesday’s trading session at 12:22 PM EST. This sharp ...
TG Therapeutics price target raised to $10 from $9 at BofA
BofA raised the firm’s price target on TG Therapeutics (TGTX) to $10 from $9 and keeps an Underperform rating on the shares. While political and rate uncertainty continues to be an overhang, the firm ...
Vir Biotechnology’s Early Stage Developments and Valuation Lead to Hold Rating Amid Long-Term Promise and Near-Term Uncertainties
Eric Joseph, an analyst from J.P. Morgan, maintained the Hold rating on Vir Biotechnology (VIR – Research Report). The associated price target ...